Molecular mechanisms for the persistent bronchodilatory effect of the β2‐adrenoceptor agonist salmeterol
- 25 August 2009
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 158 (1), 183-194
- https://doi.org/10.1111/j.1476-5381.2009.00296.x
Abstract
Beta(2)-adrenoceptor agonists are effective bronchodilators. In vitro studies demonstrated long-lasting airway smooth muscle relaxation by salmeterol after washout, the quick disappearance of this effect in presence of antagonists and its recovery after antagonist removal. Current explanations invoke salmeterol accumulation in the membrane ('diffusion microkinetic' model) or the existence of salmeterol-binding 'exosites'. An alternative model based on 'rebinding' of a dissociated ligand to the receptor molecules also produces an apparent decrease in the ligand's dissociation rate in the absence of competing ligands. PURPOSE AND APPROACH: Computer-assisted simulations were performed to follow the receptor-occupation by a salmeterol-like ligand and a competing ligand as a function of time. The aptness of the models to describe the above in vitro findings was evaluated. The 'diffusion microkinetic' model is sufficient to explain a long-lasting beta(2)-adrenoceptor stimulation and reassertion as long as the membrane harbors a high concentration of the agonist. At lower concentration, 'rebinding' and, in second place, 'exosite' binding are likely to become operational. The 'rebinding' and 'exosite' binding mechanisms take place at a sub-cellular/molecular scale. Pending their demonstration by experiments on appropriate, simple models such as intact cells or membranes thereof, these mechanisms remain hypothetical in the case of salmeterol. Airway smooth muscle contraction could also be governed by additional mechanisms that are particular to this macroscopic approach.Keywords
This publication has 53 references indexed in Scilit:
- Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptorBritish Journal of Pharmacology, 2007
- Molecular mechanisms of β2-adrenergic receptor function, response, and regulationJournal of Allergy and Clinical Immunology, 2006
- Serial rebinding of ligands to clustered receptors as exemplified by bacterial chemotaxisPhysical Biology, 2005
- ?2-Adrenergic receptor signaling complexes in cardiomyocyte caveolae/lipid rafts*1Journal of Molecular and Cellular Cardiology, 2004
- Structure and Dynamics of Micelle-bound Neuropeptide Y: Comparison with Unligated NPY and Implications for Receptor SelectionJournal of Molecular Biology, 2001
- Probing the Salmeterol Binding Site on the β2-Adrenergic Receptor Using a Novel Photoaffinity Ligand, [125I]IodoazidosalmeterolBiochemistry, 1999
- Sustained Activation of a G Protein-coupled Receptor via “Anchored” Agonist BindingPublished by Elsevier BV ,1996
- Formoterol: Pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective β2-adrenoceptor agonist bronchodilatorLife Sciences, 1993
- The pharmacology of salmeterolLife Sciences, 1993
- Aggregation of IgE-receptor complexes on rat basophilic leukemia cells does not change the intrinsic affinity but can alter the kinetics of the ligand-IgE interactionBiochemistry, 1992